Acceleron Pharma Inc. (NASDAQ:XLRN) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.61 per share.
Looking ahead, the full year loss are expected at $ 2.49 per share on the revenues of $ 98.14 million.
Previous Quarter Performance
Acceleron Pharma Inc. outlined loss for the second quarter of $ 0.34 per share, from the revenue of $ 39.75 million. The quarterly revenues developed 43.66 percent compared with the same quarter last year. According to street consensus, XLRN was expected to report 2Q20 loss of $ 0.57 per share from revenue of $ 30.08 million. The bottom line results beat street analysts by $ 0.23 or 40.35 percent, at the same time, top line results outshined analysts by $ 9.67 million or 32.15 percent.
Stock Performance
Shares of Acceleron Pharma Inc. traded up $ 6.88 or 6.62 percent on Wednesday, reaching $ 110.88 with volume of 311.60 thousand shares. Acceleron Pharma Inc. has traded high as $ 112.54 and has cracked $ 107.11 on the downward trend
The closing price of $ 110.88, representing a 159.03 % increase from the 52 week low of $ 40.15 and a 16.14 % decrease over the 52 week high of $ 124.01.
The company has a market capital of $ 6.64 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Overweight rating, with $ 125.00 target price.
Conference Call
Acceleron Pharma Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.acceleronpharma.com
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension.
